MITF is a driver of a reversible non-mutational drug-tolerance phase in melanoma
Drug repositioning identifies nelfinavir mesylate as a suppressor of MITF expression
Nelfinavir sensitizes BRAF and NRAS mutant melanoma to MAPK inhibitor treatment
A nelfinavir combination therapy overcomes NRAS-driven acquired resistance